Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Verena Braun |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment / Sven Ulrich en Journal of Clinical Psychopharmacology, Año 2000 - Vol. 20 - No. 2 (Abril)
[artículo]
Título : Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment Tipo de documento: texto impreso Autores: Sven Ulrich, Autor ; Sabine Neuhof, Autor ; Verena Braun, Autor Fecha de publicación: 2023 Artículo en la página: pp. 210-219 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Haloperidol, Compuestos de piridinio, Esquizofrenia. Resumen: In an open clinical trial, serum concentrations of haloperidol pyridinium (CHP+) and reduced haloperidol pyridinium (CRHP+), as well as haloperidol (CH) and reduced haloperidol (CRH), were measured in 57 schizophrenic and schizoaffective inpatients during 6 weeks of short-term treatment. Psychopathology was monitored with the Brief Psychiatric Rating Scale (BPRS), and extrapyramidal adverse effects were assessed with the Extrapyramidal Symptom Rating Scale (EPS). Link: ./index.php?lvl=notice_display&id=31217
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 2 (Abril) . - pp. 210-219[artículo] Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment [texto impreso] / Sven Ulrich, Autor ; Sabine Neuhof, Autor ; Verena Braun, Autor . - 2023 . - pp. 210-219.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 2 (Abril) . - pp. 210-219
Palabras clave: Antipsicóticos, Haloperidol, Compuestos de piridinio, Esquizofrenia. Resumen: In an open clinical trial, serum concentrations of haloperidol pyridinium (CHP+) and reduced haloperidol pyridinium (CRHP+), as well as haloperidol (CH) and reduced haloperidol (CRH), were measured in 57 schizophrenic and schizoaffective inpatients during 6 weeks of short-term treatment. Psychopathology was monitored with the Brief Psychiatric Rating Scale (BPRS), and extrapyramidal adverse effects were assessed with the Extrapyramidal Symptom Rating Scale (EPS). Link: ./index.php?lvl=notice_display&id=31217